Show simple item record

dc.contributor.authorCardoso, F.
dc.contributor.authorLin, C.
dc.contributor.authorGradishar, W.
dc.contributor.authorAzevedo, S.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorBachelot, T.
dc.contributor.authorRoyce, M.
dc.contributor.authorVillanueva, C.
dc.contributor.authorMelo Cruz, F.
dc.contributor.authorHegg, R.
dc.contributor.authorFalkson, C.
dc.contributor.authorJeong, J.
dc.contributor.authorSrimuninnimit, V.
dc.contributor.authorArce, C. H.
dc.contributor.authorRidolfi, A.
dc.date.accessioned2021-03-03T19:08:09Z
dc.date.available2021-03-03T19:08:09Z
dc.identifier.citationBachelot T., Royce M., Villanueva C., Melo Cruz F., Hegg R., Falkson C., Jeong J., Srimuninnimit V., Arce C. H. , Ridolfi A., et al., "Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4", 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, İspanya, 8 - 12 Eylül 2017, cilt.28
dc.identifier.othervv_1032021
dc.identifier.otherav_52e581a7-2c23-44e6-9ca3-8f094a81f02d
dc.identifier.urihttp://hdl.handle.net/20.500.12627/58814
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectONKOLOJİ
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.titleEverolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4
dc.typeBildiri
dc.contributor.departmentUNICANCER , ,
dc.identifier.volume28
dc.contributor.firstauthorID152192


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record